BILL ANALYSIS

HR8943

BEARISH

Our Doctors First Act of 2026

HR8943 (Our Doctors First Act of 2026) has been assessed with a bearish outlook for investors. This legislation directly affects HCA Healthcare ($HCA), $UHS and $THC. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bearish

Market Sentiment

3

Affected Stocks

1

Sectors Impacted

Key Takeaways for Investors

1

Bill is early-stage with low passage probability

2

No direct funding or tax changes; restricts existing Medicare GME payments

3

For-profit hospital operators face modest operational risk if enacted

How HR8943 Affects the Market

The bill has minimal market implications at this stage. If it gains traction, for-profit hospital operators like HCA, UHS, and THC could face increased labor costs from replacing non-citizen residents, but the effect on earnings would be small (less than 1% of revenue). No bullish signals for any sector.

Bill Details

MetricValue
Bill NumberHR8943
Market Sentimentbearish
Event Date
Affected SectorsHealthcare
Affected StocksHCA Healthcare ($HCA), $UHS, $THC
SourceView on Congress.gov →

Summary

HR8943 (Our Doctors First Act) would ban Medicare GME payments for non-citizen residents, imposing penalties on hospitals. The bill is in early committee stage with no companion Senate bill, making passage unlikely. For-profit hospital operators HCA, UHS, and THC face modest operational risk if enacted, but no near-term market impact.

Full AI Market Analysis

HR8943 was introduced on May 20, 2026 by Rep. Steube (R-FL) and referred to the Ways and Means and Energy and Commerce Committees. The bill amends the Social Security Act to prohibit Medicare from paying for graduate medical education costs attributable to non-citizen residents, effective one year after enactment. Hospitals that knowingly count non-citizen residents face escalating civil monetary penalties. The bill is in early stage with no Senate companion, and the 119th Congress has limited time remaining. The money trail is zero: the bill does not authorize or appropriate any funding; it restricts existing Medicare GME payments. Structural winners are US-citizen medical residents who may face less competition for slots, but no public company benefits directly. Losers are teaching hospitals that rely on non-citizen residents, particularly large academic medical centers and for-profit chains with teaching programs. HCA, UHS, and THC have exposure, but the impact is small relative to their revenue (HCA's FY2025 revenue was ~$70B; GME payments are a fraction). No real market data is provided for these tickers, so no price trend analysis is possible. The legislative timeline is uncertain: the bill must pass both committees, the House, the Senate, and be signed into law. With a Republican sponsor and divided government, passage probability is low.

Stocks Affected by HR8943

Sectors Impacted by HR8943

Related Healthcare Legislation

Understand the Terms

Track Bills Like HR8943 Daily

Get AI-analyzed alerts when Congress moves markets.

Get Started →